Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21161 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2025-05-27 (fiercebiotech.com)
5 people charged in $600K insider trading scheme tied to Novartis' Chinook acquisition: DOJ
Five people have been charged for allegedly participating in an insider trading scheme tied to
Read more
2025-05-27 (endpts.com)
Sernova chair resigns following insider trading indictment over Novartis-Chinook deal
Sernova chairman Ross Haghighat resigns after DOJ indictment on 16 insider trading counts related to Novartis' $3.2B Chinook Therapeutics acquisition in 2023.
Read more
2025-05-24 (law360.com)
Biotech Insider Traded On $3.5B Novartis Deal, Feds Say -
A former board member at Chinook Therapeutics orchestrated an insider-trading scheme after learning about Novartis' plans to purchase the biotech company for $3.5 billion in 2023, according to an indictment announced Friday.
Read more
2025-03-31 (law360.co.uk)
Novartis, Genentech Lose Asthma Drug Patent In Netherlands -
Celltrion Inc. has persuaded a Dutch court to revoke Novartis and Genentech's patent in the Netherlands for asthma drug omalizumab, straying from a London judge's recent decision to uphold the U.K. part of the patent.
Read more
2025-01-24 (benzinga.com)
Insider Decision Unfolding At Incyte: Matteo Trotta Exercises Options, Resulting In $0 - Incyte (NASDAQ:INCY) -
A significant insider transaction involving the exercise of company stock options was reported on January 22, by Matteo Trotta, EVP at Incyte INCY, as per the latest SEC filing.
Read more
2024-10-03 (aktien-und-etf.de)
Zurich stock exchange and Europe in the red: SLI and STOXX 50 weaken on Thursday afternoon
The Zurich stock exchange and Europe's STOXX 50 posted losses at midday on Thursday, while a Briton made millions for insider trading with hacked knowledge.
Read more
2023-07-09 (finanzen.ch)
Press review from weekend 28 (08/09 July)
Zurich (awp) - Below is a selection of articles on business-related topics from the press over the weekend: SNB: According to the SNB, the banks...
Read more
2023-06-27 (finanzen.ch)
Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice
Leading Breast Pump Brand Hosts Global Event to Advance Breastfeeding Research and Understand Current Hospital-Based Practices, Sharing Research F...
Read more
2023-06-22 (finanzen.ch)
FDA Inspection Blitz Leads to More Than 180 Warning Letters to Retailers for the Illegal Sale of Youth-Appealing Elf Bar and Esco Bars E-Cigarettes
Calls to Poison Centers About Elf Bar Exposure Among Children Under 5 Raise Concerns SILVER SPRING, Md., June 22, 2023 /PRNewswire/ -- Today, the U...
Read more
2022-12-29 (cash.ch)
With these Swiss shares, the cash Insider enters 2023
The cash Insider reveals which ten Swiss stocks he is going into the new stock market year with. There are some surprising changes. Unlike a year ago, the stock market forecasts of the banks and their strategists are pretty gloomy. Those of the goods in the last few weeks and months
Read more
2022-09-21 (fiercepharma.com)
Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court |
After back-to-back setbacks in its high-stakes Gilenya patent defense, Novartis is taking its arguments all the way to the Supreme Court. | After the U.S. Court of Appeals rejected its bid to rehear a negative decision on its Gilenya patent, Novartis will turn to the Supreme Court to defend its patent against generics.
Read more
2022-08-30 (fiercepharma.com)
Novartis hit with Entresto patent suit from universities amid legal fight with generics makers
Novartis is already suing a long list of generics producers that aim to bring copycats of the company's popular heart failure drug Entresto to market. | Novartis is already suing a long list of generics producers that aim to bring copycats of the Swiss pharma's popular heart failure drug Entresto to market. Now, the company itself has become target in a patent infringement lawsuit.
Read more